Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1...

  • Main
  • 2020 / 09
  • Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1...

Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab -paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system

Shimabukuro Ho, Rodrigo, Mioti Sebastião, Mariana, Venezian de Carvalho, João Paulo, Neves, Tomás, Nussbaum, Micha
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Journal of Medical Economics
DOI:
10.1080/13696998.2020.1821039
Date:
September, 2020
File:
PDF, 883 KB
2020
Conversion to is in progress
Conversion to is failed